Dynavax Technologies Corp (DVAX) 1.40 $DVAX
Why Dynavax Technologies Corporation Should Be on Your Watchlist
George Budwell, The Motley Fool - Motley Fool - Thu May 08, 5:30PM CDT
Vaccines are one of the fastest growing segments of the health care industry, with the total value of the market expected to nearly triple by 2022. Investors looking for a way to capture some of this growth, however, are generally limited to...
Technical Recap on Biotech Equities -- Research on Hemispherx Biopharma, Orexigen Therapeutics, Dynavax Technologies, and Synergy Pharma
PR Newswire - Thu May 08, 1:30PM CDT
On Wednesday, May 07, 2014, the NASDAQ Composite ended at 4,067.67, down 0.32%, the Dow Jones Industrial Average finished the day 0.72% higher at 16,518.54, and the S&P 500 closed at 1,878.21, up 0.56%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 668.01, up 0.23%, and the index has advanced 0.50% in the last one month. Investor-Edge has initiated coverage on the following equities: Hemispherx Biopharma Inc. (NYSE MKT: HEB), Orexigen Therapeutics Inc. (NASDAQ: OREX), Dynavax Technologies Corporation (NASDAQ: DVAX) and Synergy Pharmaceuticals Inc. (NASDAQ: SGYP). Free technical research on HEB, OREX, DVAX and SGYP can be downloaded upon signing up at:
Dynavax Reports In Line Q1 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 10:50AM CDT
Dynavax Technologies Corporation (DVAX) reported a loss of 5 cents per share in the first quarter of 2014, in line with the Zacks Consensus Estimate.
Dynavax Reports First Quarter 2014 Financial Results
Marketwire - Mon May 05, 8:03AM CDT
Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the first quarter ended March 31, 2014. The Company had $177.7 million in cash, cash equivalents and marketable securities as of March 31, 2014.
Research and Markets: PharmaPoint Report 2014: Prophylactic Hepatitis B Virus Vaccines - Current and Future Players - GSK, Merck, Sanofi, Kaketsuken, Dynavax Technologies
Business Wire - Mon Apr 28, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wlpkbs/pharmapoint) has announced the addition of the "PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Current and Future Players" report to their offering.
PharmaPoint Report 2014: Prophylactic Hepatitis B Virus Vaccines - Current and Future Players - GSK, Merck, Sanofi, Kaketsuken, Dynavax Technologies
M2 - Mon Apr 28, 3:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c8gl3q/pharmapoint) has announced the addition of the "PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Current and Future Players" report to their offering. PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Prophylactic hepatitis B virus vaccines Market. The report identifies and analyses the key companies shaping and driving the global prophylactic hepatitis B virus vaccines market. The report provides insight into the competitive prophylactic hepatitis B virus vaccines landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by Our team of industry experts. Scope - Investigation of current and future market competition for prophylactic hepatitis B virus vaccines - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of prophylactic hepatitis B virus vaccines sector through market impact analysis, future market scenario and company analysis Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Market Outlook 3.1 Global Markets 3.1.1 Forecast 3.1.2 Drivers and Barriers - Global Issues 4 Current and Future Players 4.1 Overview 4.2 Trends in Corporate Strategy 4.3 Company Profiles 4.3.1 GSK 4.3.2 Merck 4.3.3 Sanofi 4.3.4 Kaketsuken 4.3.5 Dynavax Technologies 5 Appendix Companies Mentioned - GSK - Merck - Sanofi - Kaketsuken - Dynavax Technologies For more information visit http://www.researchandmarkets.com/research/c8...harmapoint
Ambit Biosciences Slumps: AMBI Falls 7.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 7:49AM CDT
Ambit Biosciences saw a big move last session, as the company’s shares fell by over 7% on the day
Good News for Cleveland BioLabs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 4:20PM CDT
Cleveland BioLabs announced that it has achieved all objectives in a phase I trial on oncology candidate, CBL0102 (quinacrine).
What Falling Estimates & Price Mean for Discovery Laboratories (DSCO) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 7:33AM CDT
A stock that investors may want to consider dropping is Discovery Laboratories Inc. (DSCO)
Dynavax Starts Phase III Study on Heplisav-B - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 3:10PM CDT
Dynavax Technologies commenced a new phase III study (HBV-23) on its hepatitis B vaccine candidate, Heplisav-B
Dynavax Technologies Down 5.3%, Shares Slide into the Red (DVAX)
Comtex SmarTrend(R) - Tue Apr 15, 12:47PM CDT
Dynavax Technologies (NASDAQ
VAX) is one of today's worst performing low-priced stocks, down 5.3% to $1.42 on 1.1x average daily volume. Dynavax Technologies has traded 3.4 million shares thus far today, vs. average volume of 3.2 million shares per day. The stock has underperformed the Dow (-5.3% to the Dow's -0.2%) and underperformed the S&P 500 (-5.3% to the S&P's -0.2%) during today's trading.
Tuesday’s Top Health Care Stories: Johnson & Johnson, Teva, Mylan, and Dynavax
Leo Sun, The Motley Fool - Motley Fool - Tue Apr 15, 8:24AM CDT
Let's take a quick look at four stocks -- Johnson & Johnson , Teva , Mylan , and Dynavax -- which could all loom large in health care news this Tuesday morning. Johnson & Johnson reports first quarter earnings, raises...
Dynavax Initiates Phase 3 Study of HEPLISAV-B(TM)
Marketwire - Tue Apr 15, 5:01AM CDT
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced initiation of a new phase 3 clinical trial of HEPLISAV-B, its investigational adult hepatitis B vaccine. This large safety and immunogenicity study (known as HBV-23) was designed to address the Complete Response Letter regarding the HEPLISAV-B Biologics License Application that was issued to Dynavax by the U.S. Food and Drug Administration in February, 2013.
Health Care Sector Stocks under Review -- Research on Endo Intl., Dynavax Technologies, Forest Laboratories, and Orexigen Therapeutics
PR Newswire - Wed Apr 09, 9:14AM CDT
On Tuesday, April 08, 2014, the NASDAQ Composite ended at 4,112.99, up 0.81%, the Dow Jones Industrial Average advanced 0.06% to 16,256.14, and the S&P 500 closed at 1,851.96, up 0.38%. The gains were broad based as seven out of 10 sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 659.34, down 0.80%, and the same has fallen by 4.04% in the last one month. Investor-Edge has initiated coverage on the following equities: Endo International PLC (NASDAQ: ENDP), Dynavax Technologies Corp. (NASDAQ: DVAX), Forest Laboratories Inc. (NYSE: FRX) and Orexigen Therapeutics Inc. (NASDAQ: OREX). Free technical research on ENDP, DVAX, FRX and OREX can be downloaded upon signing up at:
Hepatitis B Vaccine Market to Experience Modest Growth Despite Upcoming Product Launches
M2 - Tue Mar 25, 4:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/398z3d/pharmapoint) has announced the addition of the "PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Global Drug Forecast and Market Analysis to 2022" report to their offering. Hepatitis B Vaccine Market to Experience Modest Growth Despite Upcoming Product Launches The global hepatitis B virus (HBV) vaccine market value will experience modest growth over the coming years, climbing from approximately $959.9 million in 2012 to $1.19 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 2.2%. Out of the eight major markets the US, Canada, France, Germany, Italy, Spain, the UK and Japan the majority of HBV vaccine sales will take place in the US, which will boast a higher CAGR of 3.4% and expand its market share from 55% to 61.7% during the forecast period. The US will be followed by Canada and the five European countries, with expected CAGRs of 1% and 0.5%, respectively. The growth in HBV vaccine sales will result from the launch of Dynavax Technologies' Heplisav and Sanofi Pasteur MSD's Hexyon, with peak-year sales anticipated to reach $85 million and $520 million, respectively. Christopher Pace, Ph.D., The report Analyst covering Infectious Diseases, says: Dynavax hopes to leverage Heplisav's superior immunogenicity and dosing regimen to increase HBV vaccine uptake in the adult market. On the other hand, Sanofi Pasteur MSD is positioning Hexyon to be the first fully liquid pediatric hexavalent vaccine. However, the authors believe that inadequate HBV vaccination coverage rates in certain high-risk populations represents one of the most important unmet needs in the marketplace. Pace says: In the pediatric segment, companies are leveraging combination vaccines to increase HBV vaccine uptake, while improved dosing regimens are necessary to increase vaccination coverage rates in adults. For both children and adults, these companies must ensure that physicians understand immunization recommendations and are able to effectively identify patients. Overall, ensuring high coverage rates will be essential to the commercial success of HBV vaccines during the forecast period. This report provides an overview of hepatitis B virus (HBV), including etiology, general symptoms from infection, and country-specific immunization recommendations and vaccination coverage data. It also gives annualized HBV vaccine market revenue, annual cost of vaccination and treatment usage pattern data from 2012 to 2022. Key Topics Covered: List of Tables List of Figures Introduction Disease Overview Vaccination Recommendations and Coverage Rates Competitive Assessment Opportunity and Unmet Need Pipeline Assessment Current and Future Players Market Outlook Appendix Companies Mentioned GSK Merck Sanofi Kaketsuken Dynavax Technologies For more information visit http://www.researchandmarkets.com/research/39...harmapoint About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Does Mannkind Offer a Good Risk to Reward Ratio?
George Budwell, The Motley Fool - Motley Fool - Fri Mar 21, 5:30PM CDT
It seems there is never a dull moment in the health care sector. On nearly a daily basis, some company is soaring to new heights or sinking like a stone. And most of the really big moves in the sector, up or down, are tied to a pivotal regulatory...
Health Car Sector Equities Technical Insight -- Research on Dynavax Technologies, Forest Laboratories, Orexigen Therapeutics and Endo Inl.
PR Newswire - Fri Mar 21, 9:08AM CDT
On Thursday, March 20, 2014, the NASDAQ Composite ended at 4,319.29, up 0.27%, the Dow Jones Industrial Average gained 0.67% to 16,331.05, and the S&P 500 closed at 1,872.01, up 0.60%. The gains were broad based as nine of ten sectors finished higher. The S&P 500 Health Care Sector Index finished the day at 686.29, down 0.02%, while the same has gained 7.91% in the last three months. Investor-Edge has initiated coverage on the following equities: Dynavax Technologies Corp. (NASDAQ: DVAX), Forest Laboratories Inc. (NYSE: FRX), Orexigen Therapeutics Inc. (NASDAQ: OREX) and Endo International PLC (NASDAQ: ENDP). Free technical research on DVAX, FRX, OREX and ENDP can be downloaded upon signing up at:
Looking for Bargain Biotechs? Consider Small-Cap Vaccine Makers
George Budwell, The Motley Fool - Motley Fool - Wed Mar 12, 5:30PM CDT
Growth and value are two words that have completely fallen out of the biotech lexicon of late. The adjectives 'bubble' and 'expensive' have instead taken their place, when investors talk biotech. And with the average biotech price to earnings ratio...
Wider Q4 Loss at Dynavax - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 8:10AM CDT
Dynavax Technologies reported a loss of 9 cents per share in the fourth quarter of 2013, wider than the Zacks Consensus Estimate of a loss of 7 cents.
Dynavax Reports Fourth Quarter and Year End 2013 Financial Results
Marketwire - Mon Mar 10, 3:01PM CDT
Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the fourth quarter and year ended December 31, 2013. The Company had $189.4 million in cash, cash equivalents and marketable securities as of December 31, 2013.
Why Dynavax Technologies Corporation Should Be on Your Watchlist
George Budwell, The Motley Fool - Motley Fool - Thu May 08, 5:30PM CDT
Vaccines are one of the fastest growing segments of the health care industry, with the total value of the market expected to nearly triple by 2022. Investors looking for a way to capture some of this growth, however, are generally limited to...
Technical Recap on Biotech Equities -- Research on Hemispherx Biopharma, Orexigen Therapeutics, Dynavax Technologies, and Synergy Pharma
PR Newswire - Thu May 08, 1:30PM CDT
On Wednesday, May 07, 2014, the NASDAQ Composite ended at 4,067.67, down 0.32%, the Dow Jones Industrial Average finished the day 0.72% higher at 16,518.54, and the S&P 500 closed at 1,878.21, up 0.56%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 668.01, up 0.23%, and the index has advanced 0.50% in the last one month. Investor-Edge has initiated coverage on the following equities: Hemispherx Biopharma Inc. (NYSE MKT: HEB), Orexigen Therapeutics Inc. (NASDAQ: OREX), Dynavax Technologies Corporation (NASDAQ: DVAX) and Synergy Pharmaceuticals Inc. (NASDAQ: SGYP). Free technical research on HEB, OREX, DVAX and SGYP can be downloaded upon signing up at:
Dynavax Reports In Line Q1 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 10:50AM CDT
Dynavax Technologies Corporation (DVAX) reported a loss of 5 cents per share in the first quarter of 2014, in line with the Zacks Consensus Estimate.
Dynavax Reports First Quarter 2014 Financial Results
Marketwire - Mon May 05, 8:03AM CDT
Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the first quarter ended March 31, 2014. The Company had $177.7 million in cash, cash equivalents and marketable securities as of March 31, 2014.
Research and Markets: PharmaPoint Report 2014: Prophylactic Hepatitis B Virus Vaccines - Current and Future Players - GSK, Merck, Sanofi, Kaketsuken, Dynavax Technologies
Business Wire - Mon Apr 28, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wlpkbs/pharmapoint) has announced the addition of the "PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Current and Future Players" report to their offering.
PharmaPoint Report 2014: Prophylactic Hepatitis B Virus Vaccines - Current and Future Players - GSK, Merck, Sanofi, Kaketsuken, Dynavax Technologies
M2 - Mon Apr 28, 3:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c8gl3q/pharmapoint) has announced the addition of the "PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Current and Future Players" report to their offering. PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Prophylactic hepatitis B virus vaccines Market. The report identifies and analyses the key companies shaping and driving the global prophylactic hepatitis B virus vaccines market. The report provides insight into the competitive prophylactic hepatitis B virus vaccines landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by Our team of industry experts. Scope - Investigation of current and future market competition for prophylactic hepatitis B virus vaccines - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of prophylactic hepatitis B virus vaccines sector through market impact analysis, future market scenario and company analysis Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Market Outlook 3.1 Global Markets 3.1.1 Forecast 3.1.2 Drivers and Barriers - Global Issues 4 Current and Future Players 4.1 Overview 4.2 Trends in Corporate Strategy 4.3 Company Profiles 4.3.1 GSK 4.3.2 Merck 4.3.3 Sanofi 4.3.4 Kaketsuken 4.3.5 Dynavax Technologies 5 Appendix Companies Mentioned - GSK - Merck - Sanofi - Kaketsuken - Dynavax Technologies For more information visit http://www.researchandmarkets.com/research/c8...harmapoint
Ambit Biosciences Slumps: AMBI Falls 7.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 7:49AM CDT
Ambit Biosciences saw a big move last session, as the company’s shares fell by over 7% on the day
Good News for Cleveland BioLabs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 4:20PM CDT
Cleveland BioLabs announced that it has achieved all objectives in a phase I trial on oncology candidate, CBL0102 (quinacrine).
What Falling Estimates & Price Mean for Discovery Laboratories (DSCO) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 7:33AM CDT
A stock that investors may want to consider dropping is Discovery Laboratories Inc. (DSCO)
Dynavax Starts Phase III Study on Heplisav-B - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 3:10PM CDT
Dynavax Technologies commenced a new phase III study (HBV-23) on its hepatitis B vaccine candidate, Heplisav-B
Dynavax Technologies Down 5.3%, Shares Slide into the Red (DVAX)
Comtex SmarTrend(R) - Tue Apr 15, 12:47PM CDT
Dynavax Technologies (NASDAQ
VAX) is one of today's worst performing low-priced stocks, down 5.3% to $1.42 on 1.1x average daily volume. Dynavax Technologies has traded 3.4 million shares thus far today, vs. average volume of 3.2 million shares per day. The stock has underperformed the Dow (-5.3% to the Dow's -0.2%) and underperformed the S&P 500 (-5.3% to the S&P's -0.2%) during today's trading. Tuesday’s Top Health Care Stories: Johnson & Johnson, Teva, Mylan, and Dynavax
Leo Sun, The Motley Fool - Motley Fool - Tue Apr 15, 8:24AM CDT
Let's take a quick look at four stocks -- Johnson & Johnson , Teva , Mylan , and Dynavax -- which could all loom large in health care news this Tuesday morning. Johnson & Johnson reports first quarter earnings, raises...
Dynavax Initiates Phase 3 Study of HEPLISAV-B(TM)
Marketwire - Tue Apr 15, 5:01AM CDT
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced initiation of a new phase 3 clinical trial of HEPLISAV-B, its investigational adult hepatitis B vaccine. This large safety and immunogenicity study (known as HBV-23) was designed to address the Complete Response Letter regarding the HEPLISAV-B Biologics License Application that was issued to Dynavax by the U.S. Food and Drug Administration in February, 2013.
Health Care Sector Stocks under Review -- Research on Endo Intl., Dynavax Technologies, Forest Laboratories, and Orexigen Therapeutics
PR Newswire - Wed Apr 09, 9:14AM CDT
On Tuesday, April 08, 2014, the NASDAQ Composite ended at 4,112.99, up 0.81%, the Dow Jones Industrial Average advanced 0.06% to 16,256.14, and the S&P 500 closed at 1,851.96, up 0.38%. The gains were broad based as seven out of 10 sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 659.34, down 0.80%, and the same has fallen by 4.04% in the last one month. Investor-Edge has initiated coverage on the following equities: Endo International PLC (NASDAQ: ENDP), Dynavax Technologies Corp. (NASDAQ: DVAX), Forest Laboratories Inc. (NYSE: FRX) and Orexigen Therapeutics Inc. (NASDAQ: OREX). Free technical research on ENDP, DVAX, FRX and OREX can be downloaded upon signing up at:
Hepatitis B Vaccine Market to Experience Modest Growth Despite Upcoming Product Launches
M2 - Tue Mar 25, 4:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/398z3d/pharmapoint) has announced the addition of the "PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Global Drug Forecast and Market Analysis to 2022" report to their offering. Hepatitis B Vaccine Market to Experience Modest Growth Despite Upcoming Product Launches The global hepatitis B virus (HBV) vaccine market value will experience modest growth over the coming years, climbing from approximately $959.9 million in 2012 to $1.19 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 2.2%. Out of the eight major markets the US, Canada, France, Germany, Italy, Spain, the UK and Japan the majority of HBV vaccine sales will take place in the US, which will boast a higher CAGR of 3.4% and expand its market share from 55% to 61.7% during the forecast period. The US will be followed by Canada and the five European countries, with expected CAGRs of 1% and 0.5%, respectively. The growth in HBV vaccine sales will result from the launch of Dynavax Technologies' Heplisav and Sanofi Pasteur MSD's Hexyon, with peak-year sales anticipated to reach $85 million and $520 million, respectively. Christopher Pace, Ph.D., The report Analyst covering Infectious Diseases, says: Dynavax hopes to leverage Heplisav's superior immunogenicity and dosing regimen to increase HBV vaccine uptake in the adult market. On the other hand, Sanofi Pasteur MSD is positioning Hexyon to be the first fully liquid pediatric hexavalent vaccine. However, the authors believe that inadequate HBV vaccination coverage rates in certain high-risk populations represents one of the most important unmet needs in the marketplace. Pace says: In the pediatric segment, companies are leveraging combination vaccines to increase HBV vaccine uptake, while improved dosing regimens are necessary to increase vaccination coverage rates in adults. For both children and adults, these companies must ensure that physicians understand immunization recommendations and are able to effectively identify patients. Overall, ensuring high coverage rates will be essential to the commercial success of HBV vaccines during the forecast period. This report provides an overview of hepatitis B virus (HBV), including etiology, general symptoms from infection, and country-specific immunization recommendations and vaccination coverage data. It also gives annualized HBV vaccine market revenue, annual cost of vaccination and treatment usage pattern data from 2012 to 2022. Key Topics Covered: List of Tables List of Figures Introduction Disease Overview Vaccination Recommendations and Coverage Rates Competitive Assessment Opportunity and Unmet Need Pipeline Assessment Current and Future Players Market Outlook Appendix Companies Mentioned GSK Merck Sanofi Kaketsuken Dynavax Technologies For more information visit http://www.researchandmarkets.com/research/39...harmapoint About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Does Mannkind Offer a Good Risk to Reward Ratio?
George Budwell, The Motley Fool - Motley Fool - Fri Mar 21, 5:30PM CDT
It seems there is never a dull moment in the health care sector. On nearly a daily basis, some company is soaring to new heights or sinking like a stone. And most of the really big moves in the sector, up or down, are tied to a pivotal regulatory...
Health Car Sector Equities Technical Insight -- Research on Dynavax Technologies, Forest Laboratories, Orexigen Therapeutics and Endo Inl.
PR Newswire - Fri Mar 21, 9:08AM CDT
On Thursday, March 20, 2014, the NASDAQ Composite ended at 4,319.29, up 0.27%, the Dow Jones Industrial Average gained 0.67% to 16,331.05, and the S&P 500 closed at 1,872.01, up 0.60%. The gains were broad based as nine of ten sectors finished higher. The S&P 500 Health Care Sector Index finished the day at 686.29, down 0.02%, while the same has gained 7.91% in the last three months. Investor-Edge has initiated coverage on the following equities: Dynavax Technologies Corp. (NASDAQ: DVAX), Forest Laboratories Inc. (NYSE: FRX), Orexigen Therapeutics Inc. (NASDAQ: OREX) and Endo International PLC (NASDAQ: ENDP). Free technical research on DVAX, FRX, OREX and ENDP can be downloaded upon signing up at:
Looking for Bargain Biotechs? Consider Small-Cap Vaccine Makers
George Budwell, The Motley Fool - Motley Fool - Wed Mar 12, 5:30PM CDT
Growth and value are two words that have completely fallen out of the biotech lexicon of late. The adjectives 'bubble' and 'expensive' have instead taken their place, when investors talk biotech. And with the average biotech price to earnings ratio...
Wider Q4 Loss at Dynavax - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 8:10AM CDT
Dynavax Technologies reported a loss of 9 cents per share in the fourth quarter of 2013, wider than the Zacks Consensus Estimate of a loss of 7 cents.
Dynavax Reports Fourth Quarter and Year End 2013 Financial Results
Marketwire - Mon Mar 10, 3:01PM CDT
Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the fourth quarter and year ended December 31, 2013. The Company had $189.4 million in cash, cash equivalents and marketable securities as of December 31, 2013.
